跳至主要内容
临床试验/NCT00963326
NCT00963326已完成不适用

Morphological and Molecular Characterization of Tumors of the Aero-digestive Tract in Patients Who Have no Risk Factors Such as Alcohol, Smoking, or Occupation

Centre Oscar Lambret10 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2009年3月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
10
主要终点
Tumor response rate by RECIST criteria

研究概览

简要总结

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood and tissue samples from patients with larynx cancer, pharynx cancer, or oral cavity cancer.

详细描述

OBJECTIVES:

Primary

  • Characterize, morphologically and molecularly, squamous cell carcinoma of the larynx, pharynx, or oral cavity in patients without high-risk factors, such as alcohol consumption, smoking, or occupation.

Secondary

  • Study the impact parameters of morphology, molecular characteristics, and genomics on disease-free survival and overall survival of these patients.
  • Study the impact parameters of morphological, molecular, and genomic control in the tumor.
  • Assess, in advanced tumors, the risk of heterogeneity of morphological, molecular, and genomic control in the tumor.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
15 Years 至 120 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed squamous cell carcinoma of the larynx, pharynx, or oral cavity
  • No risk factors of alcohol consumption, smoking, or occupational hazards such as asbestos, hydrocarbons, paints, nickel, stone dust, or wood dust.
  • Must be a life-time non-smoker, not a former smoker
  • Measurable disease by RECIST criteria
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-1
  • No other serious concomitant medical conditions precluding general anesthesia
  • No psychological, familial, social, or geographical reasons that would preclude follow up
  • PRIOR CONCURRENT THERAPY:
  • Not specified

排除标准

  • 未提供

结局指标

主要结局

Tumor response rate by RECIST criteria

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验